Calixar licensing agreement with Regeneron
Calixar SAS, a biotechnology company specialized in native membrane protein stabilization, has entered into an exclusive licensing agreement with Regeneron Pharmaceuticals, Inc.... Read More
Sandoz licensing agreement with EirGenix to commercialize trastuzumab biosimilar
Posted on02 May 2019
TagsBiosimilar, biosimilar deals, biosimilar of sandoz, drug licensing, EirGenix, sandoz, trastuzumab
Comments0
Sandoz, a Novartis division and a global leader in biosimilars, has entered into an agreement to commercialize a proposed trastuzumab biosimilar. This... Read More
Novartis licenses lipoprotein-lowering CVD drug AKCEA-APO(a)-LRx
Posted on26 Feb 2019
Comments0
Excited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ AKCEA-APO(a)-LRx, a treatment to reduce the risk... Read More
How much is the ideal royalty payment in pharmaceutical industry?
A royalty payment is made to the legal owner of the property, patent, copyrighted work, or franchise by licensees or franchisees who... Read More
Eyevance Pharmaceuticals Acquires Worldwide Rights to NEXAGON®
Posted on04 Oct 2018
Comments0
Eyevance Pharmaceuticals, a Fort Worth-based pharmaceutical company committed to developing and commercializing innovative and impactful ophthalmic products, announced a worldwide licensing agreement... Read More
Case Study: Novartis Pharma’s global licensing deal to develop & commercialise MOR106
MOR106 is an investigational, fully human, IgG1 monoclonal antibody directed against the target IL-17C that was generated in a collaboration between MorphoSys... Read More
Benitec’s Axovant exclusive rights to gene therapy for OPMD
Axovant Sciences announced that it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from Benitec Biopharma for the... Read More
Deal Insight: Daiichi Sankyo, DarwinHealth R&D agreement
Daiichi Sankyo Company, Limited and DarwinHealth announced they have entered into a research agreement providing Daiichi Sankyo with exclusive access to DarwinHealth’s... Read More
Insight on XOMA Corp and Novartis Licensing Deal
Novartis has bought the rights to Xoma’s gevokizumab. Novartis AG bagged global commercial license for Xoma Corp.’s anti-IL-1 beta monoclonal antibody gevokizumab... Read More
Samsung Bioepis and Takeda’s Co-development deal for novel biologics
Korean biosimilars manufacturer Samsung Bioepis Co Ltd. will team up with Japanese drugmaker Takeda Pharmaceutical Company to jointly develop new biologic therapies.... Read More